Overview

Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)

Status:
Terminated

Trial end date:
2008-09-01

Target enrollment:

Participant gender:

Summary

In this study, adult Indonesian subjects with human immunodeficiency virus (HIV) coinfected with chronic hepatitis C (CHC) will be given peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) combination therapy. The efficacy rate (sustained virologic response, end of treatment virologic response, and sustained biochemical response), the subject morbidity rate as caused by other opportunistic infection (eg, bacterial pneumonia, tuberculosis, and other bacterial infection), and the safety and tolerability of this combination therapy will be examined.

Phase:

Phase 4

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Interferon-alpha
Peginterferon alfa-2b
Ribavirin